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ABSTRACT: Glucosamine (GlcN) is a naturally occurring amino-monosaccharide with putative chondroprotective activity. Optimum
responses to GlcN are achieved at concentrations which are impractical with oral dosing. Intra-articular delivery of a bolus dose of
GlcN is one way to overcome these pharmacokinetic obstacles. In this study we report the effects of exposing primary human
chondrocytes to a bolus dose of GlcN. We also locally administered GlcN in the context of a meniscal transection model of rat
osteoarthritis (OA). The knees of male rats were subjected to medial meniscal transection and developed arthritic changes over 4 weeks.
Treatment groups were then given thrice weekly 100mL injections of 35mg, 350mg, 1.8mg, or 3.5mg of GlcN dissolved in normal
saline. Gross images, modified Mankin scores, and histomorphometric measurements were used as outcome measures. The 350mg
dosage of GlcN had the most significant positive impact on all components of the modified Mankin score. Together, these findings
suggest the local delivery of high concentrations of GlcN is well tolerated and can suppress experimental OA through influences on
both bone and cartilage.  2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:302–309, 2014.
Keywords: glucosamine; osteoarthritis; rat arthritis; animal models
Osteoarthritis is one of the most common joint dis-
orders afflicting humans, and it is estimated that over
60% of the United States population develop radio-
graphic evidence of OA by 55 years of age.1 The
pathologic hallmarks of OA include progressive degen-
eration of articular cartilage and changes in subchon-
dral bone architecture. OA is a disease of the entire
joint organ including cartilage, subchondral bone,
synovium, ligament, and resident stem cells.2–5 The
etiology of OA is not fully understood. At the cellular
level, disease progression has been divided into a
biosynthetic and degenerative phase.6,7 The biosyn-
thetic phase begins with extracellular matrix (ECM)
damage that the chondrocytes fail to adequately
repair. During the degenerative phase, ECM produc-
tion is inhibited and the chondrocytes release proteo-
lytic enzymes which accelerate cartilage loss. The
degraded ECM products diffuse throughout the joint
ultimately leading to inflammatory changes which
perpetuate disease progression.3,6,8 Currently accept-
ed pharmacologic therapy for OA is centered on
symptomatic relief and is limited to analgesic medi-
cations, anti-inflammatory agents, and viscosuppli-
mentation. These interventions provide temporary
relief from pain and improve function; however, they
have little effect on the structural degradation of joint
tissue.9
The utility of putative chondroprotective agents
such as chondrotin sulfate and glucosamine (GlcN) are
controversial and under intense investigation. The
molecular mechanisms of GlcN remain poorly defined;
however, numerous in vitro studies demonstrate GlcN
affects multiple cell types within the joint organ
including chondrocytes, mesenchymal stem cells, syno-
viocytes, osteoblasts, and osteoclasts.10–14 The benefi-
cial effects of GlcN in vitro are frequently seen at
millimolar concentrations, which are typically 103–104
fold above those obtained with standard oral dosing.15
One potential solution to achieve higher concentra-
tions of GlcN in vivo is through an intra-articular
injection. This clearly represents a different pharmaco-
kinetic profile than continuously exposing cells to high
concentrations. Nevertheless, with appropriate dosing,
it is feasible that multiple high dose exposures could
have a significant effect. To our knowledge, there are
no published studies examining the effects of a single
bolus exposure to GlcN.
The multi-tissue involvement of OA requires the
development of in vivo models. Animal models of OA
can be achieved through natural aging processes,
genetic approaches, pharmacologic manipulation, or
through surgically induced joint instability.16–20 No
animal models fully mimic all facets of human OA and
the relevance of these models is based primarily on the
histopathological similarities to human disease.19 In
this study we characterize a surgical destabilization
technique similar to Glasson et al.21 in which the
medial meniscus of the rat is fully transected and the
medial collateral ligament is spared (MMx). Menisci
provide congruency and increase the contact area of
articulating bones which distributes contact forces
over greater areas. Surgical destabilization of the knee
focuses mechanical stresses to smaller areas and
results in arthritic changes that closely represent OA.
These models are widely accepted for evaluating both
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the pathogenesis and pharmacological management
of OA.
This study evaluated the anti-arthritic efficacy of
locally injected GlcN within the context of a rat knee
surgically destabilized through MMx. Three related
sets of experiments were carried out. First, primary
human OA chondrocytes were exposed in vitro to a
bolus dose of GlcN within a poly(ethylene glycol)
diacrylate (PEGDA) hydrogel. Hydrogels are ideal
candidates for in vitro culture of chondrocytes due to
their high water content and tissue-like elasticity.22
Outcome measures for the in vitro study include
biochemical and gene expression analysis for common-
ly accepted markers of cartilage formation. The sec-
ond study characterized the progression of untreated
OA at 4 and 8 weeks in a surgically destabilized rat
knee. Lastly, following 4 weeks of OA progression in
the rat, GlcN was delivered intra-articularly with
weekly injections for 3 weeks. Outcome measures
employed to characterize joint disease included gross
morphology, semiquantitative histopathology, and his-
tomorphometry. The experimental design is summa-
rized in Figure 1A and B. Taken together, our results
demonstrate the delivery of small molecules through
intra-articular injection is feasible, and that GlcN is




Human osteoarthritic chondrocytes were enzymatically iso-
lated as previously described.23 Briefly, the cells were
isolated from tissue obtained during total knee arthroplasty.
The knee joints were supplied by National Disease Research
Interchange (Philadelphia, PA). Cartilage explants were
digested with agitation for 16 h at 37˚C in a 0.17% w/v Type
II Collagenase solution (Worthington Biochemical Corpora-
tion, Lakewood, NJ) containing high-glucose Dulbecco’s
Modified Eagle Medium (DMEM; Gibco, Grand Island, NY)
with 6% fetal bovine serum (FBS; Hyclone, Logan, UT). The
resulting filtrate was passed through a 70-mm filter, and
cells were rinsed thoroughly with phosphate buffered saline
(PBS) containing 100U/ml penicillin and 100mg/ml strepto-
mycin (Gibco). Before encapsulation, primary chondrocytes
were passaged once in monolayer to obtain adequate cell
numbers.
Media Conditions and Cell Encapsulation
Chondrocyte growth media (CCM) consisted of high-glucose
DMEM (Gibco), 10% fetal bovine serum, 0.1mM MEM
nonessential amino acids solution (Invitrogen, Carlsbad, CA),
10mM HEPES (Invitrogen), 50mg/ml ascorbic acid, 0.4mM
proline (Sigma), 1mM sodium pyruvate (Sigma), and 100U/
ml penicillin and 100mg/ml streptomycin. Constructs were
cultured in CCM for 3 weeks in a humidified 37˚C environ-
ment with 5% CO2 and media was changed every 2–3 days
until time of harvest.
Figure 1. Experimental design for establishing the rat medial meniscal transeciton (MMx) model and evaluating the efficacy of intra-
articular delivered GlcN. Separate experimental arms were established to validate the arthritic changes following MMx at both 4 and
8 weeks post-operatively (A). GlcN is administered through single weekly injections for 3 weeks at the beginning of weeks 5, 6, and 7
(B). Representative surgical fields and landmarks for the sham and MMx are depicted in (C) and (D), respectively. MMTL, medial
meniscotibial ligament; LMTL, lateral meniscotibial ligament; MM, medial meniscus; ACL, anterior cruciate ligament.
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Three-dimensional constructs were formed, using 10%
poly(ethylene glycol) diacrylate(PEGDA) (Sun-Bio, Orinda,
CA) dissolved in PBS. The photoinitiatorIrgacure D2959
(Ciba Specialty Chemicals, Tarytown, NY) was added to the
PEGDA solution and mixed thoroughly to achieve a final
0.05% w/v concentration. Passage 1 chondrocytes were
suspended within the precursor solution at a density of
2 107 cells/ml and then transferred into a sterile cylindrical
mold followed by exposure to long wavelength 365nm light
at 4.5mW/cm2 (Glowmark Systems, Upper Saddle River, NJ)
for 5min to achieve complete gelation. To mimic a bolus dose
of GlcN, GlcN was dissolved in the precursor solution at
1mg/ml before polymerization. The constructs were analyzed
at 21 days as described below.
The initial concentration of GlcN in the construct was
1mg/ml, and when diluted into 1.5ml of media, this corre-
sponds to 50mg/ml or 0.23mM. This assumes GlcN was
distributed equally throughout the media, and ignores cellu-
lar uptake. With these same assumptions, the first media
change lowers the GlcN concentration by a factor of 20 and
occurred 36–48h after the initial encapsulation.
Biochemical Analysis
Six constructs per treatment group were collected for bio-
chemical studies. To quantify glycosaminoglycan (GAG)
content, constructs were lyophilized, weighed, and crushed
using a pellet pestle mixer (Kimble/Kontes, Vineland, NJ).
The resulting material was digested in a 125mg/ml papai-
nase solution (Worthington Biomedical, Lakewood, NJ) for
18h at 60˚C. The DNA content was determined through
fluorophotometry using Hoechst 33258 dye (Hoefer, Hollis-
ton, MA) as previously described.12 GAG content was mea-
sured using a dimethylene blue (DMMB) spectrophotometric
assay at an absorbance of 525nm. Standard curves were
generated using chondroitin sulfate. Collagen content was
determined using the hydroxyproline assay as previously
described.12 Samples were hydrolyzed for 16h at 115˚C in
6N hydrochloric acid. The resulting solutions containing 4
hydroxyproline were neutralized, oxidized with chloramine-T
hydrate, and reacted with p-dimethylaminobenzaldehyde.
Absorbance was measured at 550nm and trans-4-hydroxy-L-
proline (Sigma–Aldrich) was used as a standard.
Gene Expression
Total RNA was extracted from the 3D constructs using
TRIzol (Invitrogen) according to the manufacturer’s instruc-
tions. Complementary DNA was formed using the reverse
transcriptase Superscript First-Strand Synthesis kit (Invitro-
gen). Quantitative real-time PCR was conducted on the
following genes: aggrecan (F: CAC GAT GCC TTT CAC CAC
GAC; R: TGC GGG TCA ACA GTG CCT ATC), type II
collagen (F: GAA ACC ATC AAT GGT GGC TTCC; R: CGA
TAA CAG TCT TGC CCC ACTT), MMP-1 (F: CTG AAG GTG
ATG AAG CAG CC; R: AGT CCA AGA GAA TGG CCG AG),
MMP-2 (F: GCG ACA AGA AGT ATG GCT TC; R: TGC CAA
GGT CAA TGT CAG GA), MMP-3 (F: CTC ACA GAC CTG
ACT CGG TT; R: CAC GCC TGA AGG AAG AGA TG), and
MMP-13 (F: CTA TGG TCC AGG AGA TGA AG; R: AGA
GTC TTG CCT GTA TCC TC), MT1-MMP (F: CAA CAC TGC
CTA CGA GAG GA; R: GTT CTA CCT TCA GCT TCT GG),
and normalized to b-actin (F: TGG CAC CAC ACC TTC TAC
AAT GAGC; R: GCA CAG CTT CTC CTT AAT GTC ACGC).
All genes were analyzed in triplicates, using the 2DDCt
method. The quantification was conducted on the ABI Prism
7700 Sequence Detection System with the SYBR Green PCR
Master Mix (Invitrogen).
Surgical Induction of Joint Instability
All procedures were performed according to the Institutional
Animal Care and Use Committee at Johns Hopkins Universi-
ty School of Medicine. Six-week old male Sprague-Dawley
rats (Charles River, Germantown, MD) weighing approxi-
mately 250 g were used in these studies. Medial meniscal
transection was performed based on a modification of the
procedure utilized in the mouse by Glasson et al.21 Animals
were housed individually for the duration of the study in 15
by 30 inch cages and allowed to move without restriction.
Standard chow and water were provided ad libitum. Rats
were anesthetized with 3–5% isoflurane per standard meth-
ods and the knees were prepped for aseptic surgery. The
knee joint was exposed by a 1 cm longitudinal incision medial
to the quadriceps tendon from the proximal patella to the
proximal tibial plateau. The quadriceps tendon was subluxed
laterally and joint capsule opened with a #10 scalpel.
Recalcitrant bleeding was controlled with electrocautery. The
medial meniscus was fully transected and released 5mm
medial to the insertion of the medial meniscobtibial liga-
ment. The joint capsule, overlying muscle, and quadriceps
tendon were closed with continuous 4–0 tapered Vicryl
suture. Buprenorphrine (Reckitt and Coleman, Kingston-
Upon-Hull, UK) was administered perioperatively at
0.05mg/kg and the rats regained full mobility within 3h.
Sham surgeries were performed as described above only
the medial meniscus was spared. Rats were allocated ran-
domly to the experimental groups depicted in Figure 1A.
Control animals that underwent sham surgeries were sacri-
ficed at 8 weeks and are referred to as sham. For OA model
validation, rats were sacrificed at 4 and 8 weeks postopera-
tively and referred to as MMx 4-week or MMx 8-week,
respectively.
Intra-articular Delivery of Glucosamine
Injection therapy was initiated at the beginning of week 5
following the MMx. Each rat then received a single weekly
injection for 3 weeks as illustrated in Figure 1B. For
example, a rat allocated to the GlcN 3.5mg group would
undergo MMx at the beginning of week 1 and injections at
the beginning of weeks 5, 6, and 7. The animal would then
be sacked at the beginning of week 8.
Practice injections on cadaveric rats with Indian ink
helped to establish this technique, ensure there were no
leaks into the surrounding tissues, and also confirmed the
joint capsule had healed from the initial surgery. Rats were
anesthetized as above, and the knee joint was exposed by a
5mm longitudinal skin incision medial to the quadriceps
tendon. This provided adequate visualization of the knee and
surrounding musculature to ensure accurate placement. A
100ml dose of glucosamine hydrochloride (Sigma) dissolved
in normal saline at the indicated concentrations was admin-
istered intra articularly with a 100 27G needle using a shallow
Z track injection path medial to the trochlea. Following
injection, the knee was fully flexed and extended three times
while monitoring for leakage of injected fluid into surround-
ing tissues.
This large injection volume provides a slight resistance as
the fluid is pushed into the joint capsule. With practice, this
resistance provides confirmation of the correct placement as
the injection is difficult to administer directly into muscle or
304 GIBSON ET AL.
JOURNAL OF ORTHOPAEDIC RESEARCH FEBRUARY 2014
surrounding fascia. For a given knee, if the first injection
attempt failed it was not feasible to try a second attempt
because the fluid would leak out through the hole created in
the first attempt. All solutions were filter sterilized before
use. The skin was closed as above.
Gross Visualization and Histopathological Evaluation
The distal femur and proximal tibia were harvested en bloc
with retention of 3–4 cm of the femur and tibia. The articular
surfaces of were cleaned of menisci and loose tissue. Images
of the articular surfaces were obtained using a Zeiss dissec-
tion scope equipped with an Axiovision MRC5 digital camera.
Following imaging, samples were fixed in 10% formalin, and
decalcified with 10% formic acid. The progress of the
decalcification was followed with calcium oxalate precipita-
tion. Samples were dehydrated with ethanol and embedded
in paraffin. Coronal sections 7mm thick were collected at
100mm throughout the entire articular surface in order to
capture arthritic changes throughout the entire joint. These
sections were stained with safranin O/fast green per stan-
dard laboratory procedures. The degree of arthritic changes
were quantified with the modified Mankin Score at least
every 200mm throughout the weight bearing articular sur-
face and averaged. 18,24 Higher scores are indicative of more
sever arthritic changes while low scores are consistent with
minor disease.
Cartilage thickness was quantified using the ImageJ
analysis program (National Institutes of Health, Bethesda,
MD). Images of the articular cartilage and subchondral bone
were examined using a Nikon Eclipse TE200 microscope
with a Nikon DXM1200 camera and 10 objective. Histomor-
phometric measurements of the uncalcified and calcified
cartilage thickness were acquired from midline coronal
sections of the medial tibial plateau. For this analysis the
cartilage thickness of five different tissue sections from each
individual sample (n¼ 6) were quantified at 10 uniformly
spaced intervals.
Statistical Analysis
For in vitro studies all analyses were either done with n¼ 3
or n¼ 4, and analyzed with Student’s t-test for pair-wise
comparison. For in vivo studies, all treatment groups were
performed with n¼ 6. Mankin scores were analyzed using
the nonparametric Wilcoxon rank sum. The data are
expressed as the meanSEM and statistical significance
was noted for all p-values <0.05.
RESULTS
Response of Primary Human Chondrocytes to a Bolus Dose
of GlcN
There were no significant changes in either GAG or
total collagen matrix production when OA chondro-
cytes were exposed to GlcN (Fig. 2A). There were also
no differences in DNA content of the constructs (data
not shown). The presence of GlcN resulted in a
significant up-regulation in type IX collagen expres-
sion and down-regulation in MMP-13 and MT1-MMP
(Fig. 2B).
Cartilage Pathology Following Meniscal Transection
Meniscal transection was performed as described
above and the animals were sacrificed at 4 and 8 weeks
post-operatively. There were no immediate post-
surgical complications. No macroscopic changes repre-
sentative of OA were observed in the appearance of
the sham operated joints at either 4 or 8 weeks
(Fig. 3A and B). In contrast, 4 weeks post-operatively,
the medial compartment developed focal cartilage
erosions, osteophytes, and subchondral bone sclerosis
on both the tibia and femur (Fig. 3C and D). After
8 weeks of destabilization, severe bi-compartmental
involvement with bone eburnation was observed
(Fig. 3E and F).
The sham-operated joints had a normal gross and
histological appearance with a thin, uninterrupted
superficial layer and no evidence of proteoglycan loss
or cellularity changes. For both time points, the medial
compartment consistently developed more severe and
reproducible pathology. By 4 weeks, focal cartilage
defects with fibrillation, blistering, and proteoglycan
loss was evident (Fig. 4B). Low magnification micro-
graphs allow the comparison of overall joint changes
to the gross pathology while higher magnification
demonstrates safraninophilia, cloning, and hypocellu-
larity (Fig. 4E). Severe arthritic changes were readily
apparent following 8 weeks of destabilization (Fig. 4C
and F).
Arthritic changes occurred sequentially in a time-
dependent fashion as determined by the modified
Figure 2. Response of primary human OA chondrocytes to a
GlcN bolus within a PEGDA hydrogel. There were no significant
changes in GAG or total collagen levels (A). GlcN treatment
resulted in the up-regulation in type IX collagen and down-
regulation in MMP-13 and MT1-MMP (B). p<0.05 compared to
control.
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Mankin scores (Fig. 4G). In this model, the modified
Mankin score was significantly higher than sham at
both 4 and 8 weeks post-operatively. We used histo-
morphometric analysis to examine cartilage thickness.
Calcified cartilage thickness increased in a time de-
pendent fashion and this parameter was statistically
greater than sham knees at 8 weeks (Fig. 4H). Con-
versely, the un-calcified cartilage decreased in thick-
ness (Fig. 4I). Taken together, the data demonstrated
this model is of tunable severity as joint degeneration
increases with time.
Inhibition of OA With the Local Delivery of GlcN
There were no complications or post-surgical irregular-
ities in animals from any groups and there were no
obvious systemic effects of GlcN treatment. Treatment
groups were given thrice weekly 100ml injections of
35mg, 350mg, 1.8mg, or 3.5mg of GlcN dissolved in
normal saline 4 weeks after the initial meniscal
transection. Total time between initial surgery and
sacrifice was 8 weeks and this included 4 weeks for
arthritic changes to develop followed by 4 weeks of
treatment. Controls consisted of sham operations and
destabilized knees injected with saline alone. There
was variability in both the response to meniscal
transection and treatment efficacy, most likely due to
differences in the activity level and biomechanics of
the individual rats, which required a minimum of six
rats per group to obtain statistical significance.
The local delivery of 350mg of GlcN had the most
significant positive impact on the overall modified
Mankin score (Fig. 5A). The modified Mankin score
includes parameters for surface structure, proteogly-
can content, and cellularity changes. The positive
effects of locally delivering GlcN can be attributed to
changes in each of these parameters (Fig. 5B and D)
indicating GlcN improves the overall tissue quality at
both the cellular and organ level. GlcN also reduces
the calcified cartilage thickness and increases the
uncalcified cartilage thickness when compared to vehi-
cle injections (Fig. 5E and F).
DISCUSSION
Glucosamine is a putative chondroprotective agent
with reported efficacy in the treatment of osteoarthri-
tis. The clinical efficacy of GlcN remains controversial,
and it is difficult to reconcile discrepancies between
clinical studies because of small sample sizes, varied
patient populations, short follow-ups and differing
GlcN preparations.25–32
The intra-articular delivery of GlcN is a feasible
alternative to overcome the pharmacokinetic obstacles
associated with the oral dosing of GlcN. Our data
demonstrate that this approach is both feasible and
well tolerated. Also, the data presented in this study
suggest that primary human OA chondrocytes can
respond to a bolus dose of GlcN, and that this response
is lasting, and can be detected 21 days after the initial
exposure. To our knowledge, this is the first report to
characterize the cellular response to this pharmacoki-
netic profile. In contrast, there are several published
studies where cells are continuously exposed to elevat-
ed concentrations of GlcN for extended periods of time.
A single exposure to 1mg/ml GlcN significantly re-
duced the gene expression of MMP-13 and MT1-MMP,
two commonly studied catabolic mediators known to
Figure 3. Representative gross morphological findings of the knee articular surface 4 and 8 weeks post-operatively. Sham operated
joints showed no significant changes on either the femoral condyles or tibial plateau (A and B, respectively). Four weeks after
destabilization pathology was limited to the medial compartment and consisted of and osteophyte formation (C, arrows) opaque
changes, and fibrillations, (D, arrow). Both the medial and lateral compartments developed osteoarthritic lesions following 8 weeks of
destabilization (E and F, arrows).
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play a role in human OA.24 Similarly, GlcN exposure
significantly upregulated the expression of type IX
collagen which is highly expressed in embryonic carti-
lage, crosslinks type II collagen fibers, and its absence
is associated with a fibroblastic morphology.24–32
In vivo models are necessary to evaluate potential
OA disease modifying interventions. Intra-articular
administration of GlcN in a Vitamin A induced rabbit
OA model reduced some aspects OA progression.33
After treatment with GlcN, the articular cartilage
exhibited more homogenous cellularity and increased
staining of the cartilage matrix with Alcian Blue
although histological scoring was not possible. Howev-
er, Vitamin A induces only localized and variable OA,
in contrast to a mechanical disruption model. In our
study, we utilized a rat meniscal transection model of
OA, a mimic of posttraumatic OA. Similar surgical
destabilization models in the rat have been used to
characterize the disease modifying activity for broad-
spectrum MMP inhibitors, selective ADAMTS inhibi-
tors, FGF-18.28–29 The potential disease modifying
activity of locally administered GlcN has not been
evaluated in this system. Severe cartilage degenera-
tion occurs in rats after meniscal transection and the
Figure 4. Histological analysis of arthritic changes and quantitative assessment of cartilage thickness in the rat meniscal transection
model of osteoarthritis. Representative micrographs of the medial knee compartment stained with Safranin O. Sham operated knees
showed no arthritic changes evident at low or high magnification (A and D, respectively). Osteophytes and chondrophytes are
commonly observed in the periarticular region and increase in size and severity from 4 to 8 weeks post-operatively (B and C,
respectively). Cellular changes consistent with OA are depicted at higher magnification (E and F). The semiquantative modified
Mankin scores indicates that OA severity increases with time (G). Consistent with OA progression, increases in calcified cartilage
thickness (H) and decreases in un-calcified cartilage thickness were also observed. Statistical significance is indicated as p<0.05
compared to sham and p<0.05 compared to 4-week time point.
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cartilage lesions are morphologically and biochemically
similar to those that occur in humans. The rapid
disease progression with this model sets a high
threshold for testing therapeutic efficacy.28 Also, this
rapid progression contributes to the inherent variabili-
ty discussed above.
The roles of subchondral bone and more recently
calcified cartilage in cartilage degradation are current-
ly under investigation. Cartilage loss during OA
progression can be initiated both at the articular
surface through erosion and the osteochondral inter-
face through chondrocyte calcification and hypertro-
phy. In this study, we analyzed the calcified and un-
calcified cartilage thickness, which increased and
decreased as the arthritic changes developed. These
changes also occur in other models of OA and the data
contained herein is the second study to document
these changes in the rat.25 Interestingly, these trends
are reversed in a concentration dependent manner by
GlcN treatment. There are published in vitro studies
demonstrating GlcN influences both chondrocytes,
osteoblasts, and osteoclasts. The contributions of these
cell types to OA progression remain to be determined.
A definitive mechanism to explain the complex
actions of GlcN remains elusive and the multiple
modes of biological activity emanating from GlcN
compounds this challenge. To explain briefly, the
metabolic fate of GlcN is salvage by the hexosamine
biosynthetic pathway (HBP), thereby increasing cellu-
lar levels of UDP-GlcNAc. UDP-GlcNAc is a versatile
metabolic intermediate that potentially can provide
chondreoprotective benefits in several ways. First, it
can be used as substrate for GAG production; recent
evidence, however, where the incorporation of radio-
labeled substrates into ECM components was moni-
tored, has downplayed the importance of this
mechanism.34–35 More promisingly, UDP-GlcNAc is the
rate-determining substrate for O-GlcNAc protein modi-
fication, which is a post-translational modification of
hundreds of nucleocytosolic proteins. O-GlcNAcylation
plays a pro-survival role at low to moderate levels until
a threshold is crossed above which it contributes to
apoptotic cascades. Finally, elevated UDP-GlcNAc lev-
els contribute to the formation of highly-branched N-
glycans, a class of surface displayed epitopes that
function as ligands for galectins, proteins that produce
a cell surface lattice that sequesters signaling mole-
cules and alters their activity.36 Recent studies have
convincingly implicated this mechanism in chondro-
genesis and OA through fibronectin matrix remodeling
and activation of signaling through the epidermal
growth factor receptor and focal adhesions.37–38 Deci-
phering the relative contributions of these facets of
glucosamine activity remains a significant challenge
for ultimately understanding and fully exploiting this
sugar in tissue engineering and regenerative medicine.
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